Global HLA Typing for Transplant Market to Reach $1.8 Billion by 2030, Driven by Rising Transplant Volumes and Next-Generation Sequencing Adoption
Boston, Aug. 24, 2026 (GLOBE NEWSWIRE) -- The global HLA typing for transplant market is projected to grow from $1.2 billion in 2024 to $1.8 billion by 2030, at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2030, according to the BCC Research report Global HLA Typing for Transplant Market. BCC Research identifies accelerating adoption of high-resolution molecular typing technologies and expanding transplant infrastructure as the primary catalysts reshaping this critical segment of transplant immunology.
Key Findings
• Market trajectory: The global HLA typing for transplant market is expected to reach $1.8 billion by 2030, growing at a 6.7% CAGR from 2025 to 2030, underpinned by rising volumes of organ and hematopoietic stem cell transplants and the shift toward molecular-level compatibility assessment.
• Regional leadership: North America commands the largest regional share at 43.5%, supported by well-established transplant infrastructure, high healthcare expenditure, and strong adoption of advanced HLA typing platforms across leading transplant centers.
• Transplant demand surge: Growing incidence of blood cancers, immune deficiency disorders, liver cirrhosis, and chronic kidney disease is significantly expanding the patient population requiring transplantation — directly intensifying demand for precise HLA screening and donor-recipient matching.
• NGS and molecular typing as market accelerants: The rapid adoption of PCR-based and next-generation sequencing technologies is transforming HLA typing workflows, offering higher resolution and more accurate results than legacy serological methods. Concurrently, expansion of global donor registries and public awareness initiatives on organ donation are broadening the addressable testing pool.
• Emerging technologies redefining precision: Long-read sequencing platforms from Oxford Nanopore Technologies and PacBio (SMRT sequencing) now enable full-length HLA gene typing with read lengths of 10–25 kilobases and ultra-long reads exceeding 100 kilobases. Eplet matching compatibility analysis, AI- and ML-integrated NGS workflows, Roche's Sequencing by Expansion (SBX) technology, and the HLAMatchmaker algorithm for structural epitope mismatch identification are collectively advancing the frontier of precision transplantation and immunogenetics research.
• Competitive landscape: The market features a mix of large diagnostics and genomics incumbents alongside specialized transplant immunology players, including Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Oxford Nanopore Technologies plc., PacBio, CareDx, Agilent Technologies Inc., Revvity, BD (Becton, Dickinson and Company), GenDx, Werfen, Omixon, DiaSorin, Inno-train Diagnostik GmbH, and BAG Diagnostics GmbH.
Market Drivers
The structural growth thesis for HLA typing for transplant rests on the convergence of rising chronic disease burden and a global shift toward molecularly precise transplant medicine. Escalating rates of end-stage renal disease, hepatic failure, and hematological malignancies are expanding the transplant-eligible patient population across both developed and emerging markets, particularly in Asia-Pacific where rising incidence of chronic kidney disease and liver cirrhosis is generating meaningful new demand. Government funding commitments and transplant infrastructure investments across multiple regions are further institutionalizing HLA typing as a standard of care, while increased healthcare spending is enabling broader access to advanced clinical services.
On the technology side, the transition from low-resolution serological methods to high-resolution molecular platforms — particularly NGS — is driving both volume growth and per-test value expansion. The integration of AI and machine learning into sequencing workflows is accelerating turnaround times and enabling multiomics-based insights into transplant immunology. Compact benchtop sequencers are also opening point-of-care HLA typing applications that could decentralize testing and improve access in under-resourced settings.
Investment Considerations
For investors, the HLA typing for transplant market presents a compelling combination of durable demand drivers and technology-led margin expansion opportunities. Companies with differentiated NGS-based platforms, proprietary bioinformatics pipelines, and established relationships with transplant centers are best positioned to capture disproportionate share as the market scales. However, investors should account for meaningful headwinds: high costs of NGS and PCR-based testing limit adoption in price-sensitive markets, reimbursement frameworks remain inconsistent across geographies — particularly in India and Eastern Europe — and a persistent organ donation supply-demand gap constrains the overall transplant volume ceiling. Cultural resistance to deceased donation in Asia-Pacific and the Middle East, alongside infrastructure gaps in low- and middle-income countries, represent both near-term constraints and longer-term expansion opportunities contingent on policy and public health progress.
About the Report
Global HLA Typing for Transplant Market provides comprehensive market sizing, segmentation analysis, competitive intelligence, and forecasts covering the period 2025 to 2030.
About BCC Research
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
BCC Research LLC 50 Milk St., Ste. 16, Boston, MA 02109 press@bccresearch.com | +1 781-489-7301 www.bccresearch.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
